Class II transactivator (CIITA) isoform expression and activity in melanoma

Melanoma Research

Volumn 14, Issue 6, 2004, Pages 453-461

  Baton, Fabrice ^a   Deruyffelaere, Carine ^a   Chapin, Muriel ^a   Prod'homme, Thomas ^a   Charron, Dominique ^a   Al Daccak, Reem ^a   Alcaide Loridan, Catherine ^a  

^a INSERM   (France)

Author keywords

CREB binding protein; Cyclin D1; HLA DQ; HLA DR; Matrix metalloproteinase; Melanocyte; Melanoma; MHC class II; Transactivator

Indexed keywords

CD4 ANTIGEN; CLASS II TRANSACTIVATOR PROTEIN; CYCLIN D1; HLA D ANTIGEN; HLA DR ANTIGEN; ISOPROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PROTEIN; TRANSACTIVATOR PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR INTERACTING PROTEIN; TUMOR ANTIGEN; TYROSINE TRANSFER RNA LIGASE; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL CELL; ANTIGEN PRESENTATION; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL CYCLE; CELL TYPE; CLONAL ANERGY; CONTROLLED STUDY; FIBROBLAST; GENE ACTIVITY; GENE CONTROL; GENE EXPRESSION REGULATION; LYMPHOCYTE; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOCYTE; MELANOMA; MELANOMA CELL; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION;

ANIMALS; B-LYMPHOCYTES; CERCOPITHECUS AETHIOPS; COS CELLS; CYCLIN D1; DISEASE PROGRESSION; EUKARYOTIC INITIATION FACTOR-3; FIBROBLASTS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MHC CLASS II; HLA-DR ANTIGENS; HUMANS; MELANOMA; NUCLEAR PROTEINS; PROTEIN ISOFORMS; PROTEINS; SKIN NEOPLASMS; TRANS-ACTIVATORS; TUMOR CELLS, CULTURED; TYROSINE-TRNA LIGASE;

EID: 13544275855     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-200412000-00004     Document Type: Article

References (45)

1. Glimcher LH, Kara CJ. Sequences and factors: a guide to MHC class II transcription. Ann Rev Immunol 1992; 10:13-50.
2. Marelli-Berg FM, Lechler RI. Antigen presentation by parenchymal cells: a route to peripheral tolerance? Immunol Rev 1999; 172:297-314.
3. Brocker EB, Suter L, Sorg C. HLA-DR antigen expression in primary melanomas of the skin. J Invest Dermatol 1984; 82:244-247
4. Ruiter DJ, Bergman W, Welvaart K, Scheffer E, van Vloten WA, Russo C, et al. Immunohistochemical analysts of malignant melanomas and nevocellular nevi with monoclonal antibodies to distinct monomorphic determinants of HLA antigens. Cancer Res 1984; 44:3930-3935.
5. Ruiter DJ, Mattijssen V, Broecker EB, Ferrone S. MHC antigens in human melanomas. Semin Cancer Biol 1991; 2:35-45.
6. West KP, Priyakumar P, Jagjivan R, Colloby PS. Can HLA-DR expression help in the routine diagnosis of malignant melanomas? Br J Dermatol 1989; 121:175-178.
7. Ostmeier H, Fuchs B, Otto F, Mawick R, Lippold A, Krieg V, et al. Prognostic immunohistochemical markers of primary human melanomas. Br J Dermatol 2001; 145:203-209.
8. Colloby PS, West KP, Fletcher A. Is poor prognosis really related to HLA-DR expression by malignant melanoma cells? Histopathology 1992; 20:411-416.
9. Manici S, Sturniolo T, Imro MA, Hammer J, Sinigaglia F, Noppen C, et al. Melanoma cells present a MAGE-3 epitope to CD4(+) cytbtoxic T cells in association with histocompatibility leukocyte antigen DR11. J Exp Med 1999; 189:871-876.
10. Zeng G, Touloukian CE, Wang X, Restifo NP, Rosenberg SA, Wang RF. Identification of CD4+ T cell epitopes from NY-ESO-1 presented by HLA-DR molecules. J Immunol 2000; 165:1153-1159.
11. Becker JC, Brabletz T, Czerny C, Termeer C, Brocker EB. Tumor escape mechanisms from immunosurveillance: induction of unresponsiveness in a specific MHC-restricted CD4+ human T cell clone by the autologous MHC class II+ melanoma. Int Immunol 1993; 5:1501-1508.
12. Becker JC, Czerny C, Brocker EB. Maintenance of clonal anergy by endogenously produced IL-10. Int Immunol 1994; 6:1605-1612.
13. Takahashi T, Chapman PB, Yang SY, Hara I, Vijayasaradhi S, Houghton AN. Reactivity of autologous CD4+ T lymphocytes against human melanoma. Evidence for a shared melanoma antigen presented by HLA-DR15. J Immunol 1995; 154:772-779.
14. Deffrennes V, Vedrenne J, Stolzenberg MC, Piskurich J, Barbieri G, Ting JP, et al. Constitutive expression of MHC class II genes in melanoma cell lines results from the transcription of class II transactivator abnormally initiated from its B cell-specific promoter. J Immunol 2001; 167:98-106.
15. Harton JA, Ting JP. Class II transactivator: mastering the art of major histocompatibility complex expression. Mol Cell Biol 2000; 20:6185-6194.
16. Reith W, Mach B. The bare lymphocyte syndrome and the regulation of MHC expression. Annu Rev Immunol 2001; 19:331-373.
17. Barbieri G, Deffrennes V, Prod'homme T, Vedrenne J, Baton F, Cortes C, et al. Isoforms of the class II transactivator protein. Int Immunol 2002; 14: 839-848.
18. Fontes JD, Jiang B, Peterlin BM. The class II trans-activator CIITA interacts with the TBP-associated factor TAFII32. Nucleic Acids Res 1997; 25:2522-2528.
19. Zhu XS, Linhoff MW, Li G, Chin KC, Maity SN, Ting JP. Transcriptional scaffold: CIITA interacts with NF-Y, RFX, and CREB to cause stereospecific regulation of the class II major histocompatibility complex promoter. Mol Cell Biol 2000; 20:6051-6061.
20. Lennon AM, Ottone C, Rigaud G, Deaven LL, Longmire J, Fellous M, et al. Isolation of a B-cell-specific promoter for the human class II transactivator. Immunogenetics 1997; 45:266-273.
21. Muhlethaler-Mottet A, Often LA, Steimle V, Mach B. Expression of MHC class II molecules in different cellular and functional compartments is controlled by differential usage of multiple promoters of the transactivator CIITA. Embo J 1997; 16:2851-2860.
22. Piskurich JF, Wang Y, Linhoff MW, White LC, Ting JP. Identification of distinct regions of 5′ flanking DNA that mediate constitutive, IFN-gamma, STAT1, and TGF-beta-regulated expression of the class II transactivator gene. J Immunol 1998; 160:233-240.
23. Nickerson K, Sisk TJ, Inohara N, Yee CS, Kennell J, Cho MC, et al. Dendritic cell-specific MHC class II transactivator contains a caspase recruitment domain that confers potent transactivation activity. J Biol Chem 2001; 276:19089-19093.
24. Sisk TJ, Gourley T, Roys S, Chang CH. MHC class II transactivator inhibits IL-4 gene transcription by competing with NF-AT to bind the coactivator CREB binding protein (CBP)/p300. J Immunol 2000; 165:2511-2517.
25. Zhu XS, Ting JP. A 36-amino-acid region of CIITA is an effective inhibitor of CBP: novel mechanism of gamma interferon-mediated suppression of collagen alpha(2)(I) and other promoters. Mol Cell Biol 2001; 21: 7078-7088.
26. Nagarajan UM, Bushey A, Boss JM. Modulation of gene expression by the MHC class II transactivator. J Immunol 2002; 169:5078-5088.
27. Chiari R, Hames G, Stroobant V, Texier C, Maillere B, Boon T, et al. Identification of a tumor-specific shared antigen derived from an Eph receptor and presented to CD4 T cells on HLA class II molecules. Cancer Res 2000; 60:4855-4863.
28. Albanese C, D'Amico M, Reutens AT, Fu M, Watanabe G, Lee RJ, et al. Activation of the cyclin D1 gene by the E1A-associated protein p300 through AP-1 inhibits cellular apoptosis. J Biol Chem 1999; 274: 34186-34195.
29. Perkins ND, Felzien LK, Betts JC, Leung K, Beach DH, Nabel GJ. Regulation of NF-kappaB by cyclin-dependent kinases associated with the p300 coactivator. Science 1997; 275:523-527.
30. Chrivia JC, Kwok RPS, Lamb N, Hagiwara M, Montminy MR, Goodman RH. Phosphorylated CREB binds specifically to the nuclear protein CBP. Nature 1993; 365:855-859.
31. Watson AJ, DeMars R, Trowbridge IS, Bach FH. Detection of a novel human class II HLA antigen. Nature 1983; 304:358-361.
32. Marti GE, Kuo MC, Shaw S, Chang CC, Demars R, Sogn JA, et al. A novel HLA-D/DR-like antigen specific for human B lymphoid cells. Biochemical evidence for similarity to but nonidentity with known HLA-D/DR antigens. J Exp Med 1983; 158:1924-1937.
33. Wakasugi K, Slike BM, Hood J, Ewalt KL, Cheresh DA, Schimmel P. Induction of angiogenesis by a fragment of human tyrosyl-tRNA synthetase. J Biol Chem 2002; 277:20124-20136.
34. Choy L, Derynck R. The type II transforming growth factor (TGF)-beta receptor-interacting protein TRIP-1 acts as a modulator of the TGF-beta response. J Biol Chem 1998; 273:31 455-31 462.
35. Rodeck U, Bossler A, Graeven U, Fox FE, Nowell PC, Knabbe C, et al. Transforming growth factor β production and responsiveness in normal melanocytes and melanoma cells. Cancer Res 1994; 54:575-581.
36. Ma Z, Qin H, Benveniste EN. Transcriptional suppression of matrix metalloproteinase-9 gene expression by IFN-gamma and IFN-beta: critical role of STAT-1 alpha. J Immunol 2001; 167:5150-5159.
37. Qin H, Moellinger JD, Wells A, Windsor U, Sun Y, Benveniste EN. Transcriptional suppression of matrix metalloproteinase-2 gene expression in human astroglioma cells by TNF-alpha and IFN-gamma. J Immunol 1998; 161:6664-6673.
38. Hofmann UB, Westphal JR, Van Muijen GN, Ruiter DJ. Matrix metalloproteinases in human melanoma. J Invest Dermatol 2000; 115: 337-344.
39. Chan HM, La Thangue NB. p300/CBP proteins: HATs for transcriptional bridges and scaffolds. J Cell Sci 2001; 114:2363-2373.
40. Schnappauf F, Hake SB, Camacho Carvajal MM, Bontron S, Lisowska-Grospierre B, Steimle V. N-terminal destruction signals lead to rapid degradation of the major histocompatibility complex class II transactivator CIITA. Eur J Immunol 2003; 33:2337-2347.
41. Alcaide-Loridan C, Lennon AM, Bono MR, Barbouche R, Dellagi K, Fellous M. Differential expression of MHC class II isotype chains. Microbes Infect 1999; 1:929-934.
42. Otten LA, Steimle V, Bontron S, Mach B. Quantitative control of MHC class II expression by the transactivator CIITA. Eur J Immunol 1998; 28: 473-478.
43. Bateman AC, Turner SJ, Theaker JM, Howell WM. HLA-DQB1 *0303 and *0301 alleles influence susceptibility to and prognosis in cutaneous malignant melanoma in the British Caucasian population. Tissue Antigens 1998; 52:67-73.
44. Lee JE, Lu M, Mansfield PF, Platsoucas CD, Reveille JD, Ross MI. Malignant melanoma: relationship of the human leukocyte antigen class II gene DQB1 *0301 to disease recurrence in American Joint Committee on Cancer Stage I or II. Cancer 1996; 78:758-763.
45. Aoudjit F, Guo W, Gagnon-Houde JV, Castaigne JG, Alcaide-Loridan C, Charron D, et al. HLA-DR signaling inhibits Fas-mediated apoptosis in A375 melanoma cells. Exp Cell Res 2004; 299:79-90.